Liminal BioSciences is a global clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases with a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada,  and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market (LMNL).

On October 15, 2021 the Company closed on the divestment of the remainder of its plasma-derived therapeutics business to focus solely on its small molecule therapeutics pipeline.

 

Subscribe here to receive Liminal's latest news by email.     

Stock Quote
NASDAQLMNL
Recent News
Jan 19, 2022
Liminal BioSciences Announces Strategic Priorities For 2022

Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today provided an update in which it outlined key corporate and research and development priorities for 2022....

Nov 15, 2021
Liminal BioSciences Reports Third Quarter 2021 Financial Results

LAVAL, CANADA, and CAMBRIDGE, ENGLAND – November 15, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), today reported its financial results for...

Oct 15, 2021
Liminal BioSciences Announces Closing of Sale of Remaining Plasma-Derived Therapeutics Business

LAVAL, CANADA, and CAMBRIDGE, ENGLAND – October 15, 2021 – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), announced today that it has closed on the...

Webcasts
Liminal BioSciences Inc. – Second Quarter 2021 Results
Tuesday, August 17, 2021
8:15am EDT
Investor Contacts

Investor Relations

Shrinal Inamdar
Investor Relations and Communications Manager
+1.450.781.0115
investor@liminalbiosciences.com